{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:14:18Z","timestamp":1794654858241,"version":"4.9.1"},"reference-count":212,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Antibiotics are frequently used in patients receiving intermittent or continuous renal replacement therapy (RRT). Continuous renal replacement may alter the pharmacokinetics (PK) and the ability to achieve PK\/pharmacodynamic (PD) targets. Therapeutic drug monitoring (TDM) could help evaluate drug exposure and guide antibiotic dosage adjustment. The present review describes recent TDM data on antibiotic exposure and PK\/PD target attainment (TA) in patients receiving intermittent or continuous RRT, proposing practical guidelines for performing TDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Studies on antibiotic TDM performed in patients receiving intermittent or continuous RRT published between 2000 and 2020 were searched and assessed. The authors focused on studies that reported data on PK\/PD TA. TDM recommendations were based on clinically relevant PK\/PD relationships and previously published guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 2383 reports were retrieved. After excluding nonrelevant publications, 139 articles were selected. Overall, 107 studies reported PK\/PD TA for 24 agents. Data were available for various intermittent and continuous RRT techniques. The study design, TDM practice, and definition of PK\/PD targets were inconsistent across studies. Drug exposure and TA rates were highly variable. TDM seems to be necessary to control drug exposure in patients receiving intermittent and continuous RRT techniques, especially for antibiotics with narrow therapeutic margins and in critically ill patients. Practical recommendations can provide insights on relevant PK\/PD targets, sampling, and timing of TDM for various antibiotic classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Highly variable antibiotic exposure and TA have been reported in patients receiving intermittent or continuous RRT. TDM for aminoglycosides, beta-lactams, glycopeptides, linezolid, and colistin is recommended in patients receiving RRT and suggested for daptomycin, fluoroquinolones, and tigecycline in critically ill patients on RRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000941","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T02:00:11Z","timestamp":1636768811000},"page":"86-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review"],"prefix":"10.1097","volume":"44","author":[{"given":"Elodie","family":"Matusik","sequence":"first","affiliation":[{"name":"P\u00f4le Pharmacie & P\u00f4le Urgences-R\u00e9animation-Anesth\u00e9sie, Centre Hospitalier de Valenciennes, Valenciennes, France ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Boidin","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Service de Pharmacie, Pierre-B\u00e9nite;"},{"name":"Univ Lyon, Universit\u00e9 Claude Bernard Lyon 1, EA 3738 CICLY - Centre pour l'Innovation en Canc\u00e9rologie de Lyon, Oullins ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Friggeri","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Service d\u2019Anesth\u00e9sie, M\u00e9decine Intensive et R\u00e9animation, Pierre-B\u00e9nite ;"},{"name":"Univ Lyon, Universit\u00e9 Claude Bernard Lyon, Facult\u00e9 de M\u00e9decine Lyon Sud-Charles M\u00e9rieux, Oullins ;"},{"name":"UMR CNRS 5308, Inserm U1111, Centre International de Recherche en Infectiologie, Laboratoire des Pathog\u00e8nes \u00c9mergents ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Richard","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de M\u00e9decine Intensive R\u00e9animation, Lyon ;"},{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, INSA-Lyon, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR CNRS 5220, Inserm U1206, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bitker","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de M\u00e9decine Intensive R\u00e9animation, Lyon ;"},{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, INSA-Lyon, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR CNRS 5220, Inserm U1206, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Faculty of Medicine the University of Queensland, University of Queensland Centre for Clinical Research ;"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia;"},{"name":"Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, University of Montpellier, N\u00eemes ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-2932","authenticated-orcid":false,"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie ;"},{"name":"Univ Lyon, Universit\u00e9 Claude Bernard Lyon 1, ISPB-Facult\u00e9 de Pharmacie de Lyon ; and"},{"name":"Univ Lyon, Universit\u00e9 Claude Bernard Lyon 1, UMR CNRS 5558, Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive Villeurbanne, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2215\/CJN.11411116","article-title":"National Healthcare Safety Network (NHSN) dialysis event surveillance report for 2014","volume":"12","author":"Nguyen","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"e00583-19","DOI":"10.1128\/AAC.00583-19","article-title":"A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy","volume":"63","author":"Pistolesi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d'Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/cc13886","article-title":"\u03b2-lactam antibiotic concentrations during continuous renal replacement therapy","volume":"18","author":"Beumier","year":"2014","journal-title":"Crit Care"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.ackd.2012.10.004","article-title":"Antimicrobial dosing in acute renal replacement","volume":"20","author":"Fissell","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coph.2015.07.003","article-title":"To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt","volume":"24","author":"Wong","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000321488","article-title":"Principles of antibacterial dosing in continuous renal replacement therapy","volume":"30","author":"Choi","year":"2010","journal-title":"Blood Purif"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.reaurg.2010.03.020","article-title":"Principes de l\u2019adaptation posologique des antibiotiques lors d\u2019une \u00e9puration extrar\u00e9nale en r\u00e9animation","volume":"19","author":"Lautrette","year":"2010","journal-title":"R\u00e9animation"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.nephro.2009.02.010","article-title":"Adaptation posologique des m\u00e9dicaments couramment utilis\u00e9s en r\u00e9animation lors d\u2019\u00e9puration extrar\u00e9nale continue","volume":"5","author":"Bourquin","year":"2009","journal-title":"Nephrol Ther"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.reaurg.2005.09.006","article-title":"Pharmacocin\u00e9tique des antibiotiques et \u00e9puration extrar\u00e9nale continue","volume":"14","author":"Levraut","year":"2005","journal-title":"R\u00e9animation"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/MCC.0b013e3282f0a3d3","article-title":"Drug dosing in continuous renal replacement therapy: general rules","volume":"13","author":"Schetz","year":"2007","journal-title":"Curr Opin Crit Care"},{"key":"R15-20250603","first-page":"1","article-title":"KDIGO Clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/cc10241","article-title":"Multiple-center evaluation of mortality associated with acute kidney injury in critically ill patients: a competing risks analysis","volume":"15","author":"Clec\u2019h","year":"2011","journal-title":"Crit Care"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ndt\/gfy011","article-title":"Seasonality of acute kidney injury incidence and mortality among hospitalized patients","volume":"33","author":"Iwagami","year":"2018","journal-title":"Nephrol Dial Transpl"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/cc13716","article-title":"Variation in the use of renal replacement therapy in patients with septic shock: a substudy of the prospective multicenter observational FINNAKI study","volume":"18","author":"Poukkanen","year":"2014","journal-title":"Crit Care"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diagmicrobio.2005.12.009","article-title":"Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)","volume":"56","author":"Rhomberg","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review","volume":"2","author":"Sime","year":"2012","journal-title":"Ann Intensive Care"},{"key":"R24-20250603","first-page":"w14368","article-title":"Prolonged administration of \u03b2-lactam antibiotics\u2014a comprehensive review and critical appraisal","volume":"146","author":"Osthoff","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1294-5501(06)70794-4","article-title":"Les volumes apparents de distribution des antibiotiques: \u00e9valuation, int\u00e9r\u00eat et limites","volume":"8","author":"Bronner","year":"2006","journal-title":"Antibiotiques"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2014.01.023","article-title":"Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study","volume":"43","author":"Roberts","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","article-title":"Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis","volume":"10","author":"Velenosi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","article-title":"The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill","volume":"42","author":"Jamal","year":"2014","journal-title":"Crit Care Med"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00134-012-2706-x","article-title":"Management of renal replacement therapy in ICU patients: an international survey","volume":"39","author":"Legrand","year":"2013","journal-title":"Intensive Care Med"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000420197","article-title":"Drug removal during continuous hemofiltration or hemodialysis","volume":"93","author":"Golper","year":"1991","journal-title":"Contrib Nephrol"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2215\/CJN.05690611","article-title":"Pharmacokinetics of ampicillin\/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis","volume":"7","author":"Lorenzen","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/jac\/dky057","article-title":"Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration","volume":"73","author":"Sinnollareddy","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","article-title":"Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience","volume":"47","author":"Richter","year":"2019","journal-title":"Infection"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00228-019-02792-0","article-title":"The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF)","volume":"76","author":"Donnellan","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/hdi.12377","article-title":"Post-hemodialysis dosing of 1 vs. 2 g of ceftazidime in anuric end-stage renal disease patients on low-flux dialysis and its pharmacodynamic implications on clinical use","volume":"20","author":"Goh","year":"2016","journal-title":"Hemodial Int"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-016-0048-y","article-title":"Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study","volume":"17","author":"Descombes","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1345\/aph.1Q395","article-title":"Validation of doripenem dosing in patients with end-stage renal disease receiving hemodialysis","volume":"45","author":"Heil","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/ndt\/gfq090","article-title":"Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED)","volume":"25","author":"Deshpande","year":"2010","journal-title":"Nephrol Dial Transpl"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s13054-014-0565-2","article-title":"The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study","volume":"18","author":"Shekar","year":"2014","journal-title":"Crit Care"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clinthera.2020.02.011","article-title":"Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically ill patients receiving sustained low-efficiency dialysis","volume":"42","author":"Oliveira","year":"2020","journal-title":"Clin Ther"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"230","DOI":"10.36290\/csf.2020.032","article-title":"Meropenem serum concentrations in intensive care patients a retrospective analysis","volume":"69","author":"\u010euricov\u00e1","year":"2020","journal-title":"\u010ceska Slov Farm"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13054-018-2122-x","article-title":"Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation","volume":"22","author":"Touchard","year":"2018","journal-title":"Crit Care"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1413-8670(10)70041-6","article-title":"Vancomycin: the need to suit serum concentrations in hemodialysis patients","volume":"14","author":"Marengo","year":"2010","journal-title":"Braz J Infect Dis"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/0886022X.2016.1229992","article-title":"Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients","volume":"38","author":"Maxson","year":"2016","journal-title":"Ren Fail"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000453005","article-title":"Vancomycin during the last hour of the hemodialysis session: a pharmacokinetic analysis","volume":"135","author":"Ghouti-terki","year":"2017","journal-title":"Nephron"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5414\/CN109091","article-title":"Optimization of therapeutic drug monitoring of vancomycin in patients with chronic hemodialysis","volume":"88","author":"Mahmoud","year":"2017","journal-title":"Clin Nephrol"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/phar.2460","article-title":"Pharmacokinetics of vancomycin in critically ill patients undergoing sustained low-efficiency dialysis","volume":"40","author":"Rider","year":"2020","journal-title":"Pharmacotherapy"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/toxins12050317","article-title":"A pharmacokinetic study comparing the clearance of vancomycin during haemodialysis using medium cut-off membrane (Theranova) and high-flux membranes (Revaclear)","volume":"12","author":"Allawati","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jiac.2015.02.002","article-title":"Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections","volume":"21","author":"Nakamura","year":"2015","journal-title":"J Infect Chemother"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1097\/01.CCM.0000147687.06808.92","article-title":"Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure","volume":"32","author":"Fiaccadori","year":"2004","journal-title":"Crit Care Med"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/ndt\/gfl048","article-title":"Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation","volume":"21","author":"Fiaccadori","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-009-0766-9","article-title":"Pharmacokinetics of linezolid in septic patients with and without extended dialysis","volume":"66","author":"Swoboda","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.01650309","article-title":"Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis","volume":"4","author":"Salama","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ndt\/gfp655","article-title":"Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients","volume":"25","author":"Salama","year":"2010","journal-title":"Nephrol Dial Transpl"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0000000000000196","article-title":"Therapeutic drug monitoring of daptomycin","volume":"37","author":"Reiber","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1053\/j.ajkd.2017.05.011","article-title":"Pilot pharmacokinetic study of high-dose daptomycin in hemodialysis patients with infected medical devices","volume":"70","author":"Diolez","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijantimicag.2018.09.015","article-title":"Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution","volume":"53","author":"Galar","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/jac\/dky511","article-title":"Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy","volume":"74","author":"Schmidt","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/microorganisms8030415","article-title":"Extensive therapeutic drug monitoring of colistin in critically ill patients reveals undetected risks","volume":"8","author":"Ehrentraut","year":"2020","journal-title":"Microorganisms"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"e02430-17","DOI":"10.1128\/AAC.02430-17","article-title":"Elimination of doripenem during dialysis and pharmacokinetic evaluation of posthemodialysis dosing for patients undergoing intermittent renal replacement therapy","volume":"62","author":"Vossen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ndt\/gfn472","article-title":"Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis","volume":"24","author":"Burkhardt","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/ndt\/gfy166","article-title":"Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients","volume":"34","author":"Hsaiky","year":"2018","journal-title":"Nephrol Dial Transpl"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2215\/CJN.01600407","article-title":"Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen","volume":"2","author":"Mohamed","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/1744-9987.12810","article-title":"Gentamicin as empirical treatment in hemodialysis patients: safety, pharmacokinetics, and pharmacodynamics","volume":"23","author":"Guisado-Gil","year":"2019","journal-title":"Ther Apher Dial"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1128\/AAC.46.5.1557-1560.2002","article-title":"Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis","volume":"46","author":"Mueller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/0091270004269796","article-title":"Influence of renal function on the pharmacokinetics of piperacillin\/tazobactam in intensive care unit patients during continuous venovenous hemofiltration","volume":"45","author":"Arzuaga","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/cc10257","article-title":"Recommended \u03b2-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy","volume":"15","author":"Seyler","year":"2011","journal-title":"Crit Care"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit Care Med"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.10741011","article-title":"Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT","volume":"7","author":"Bauer","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2014.01.009","article-title":"Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"43","author":"Varghese","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/phar.1604","article-title":"Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy","volume":"35","author":"Awissi","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijantimicag.2015.02.014","article-title":"Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration","volume":"46","author":"Jamal","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijantimicag.2017.03.018","article-title":"Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients","volume":"50","author":"Roger","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R77-20250603","first-page":"39","article-title":"Pharmacokinetics and outcome of tazobactam\/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations","volume":"9","author":"Kohama","year":"2017","journal-title":"Clin Pharmacol"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s13054-020-03397-1","article-title":"Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study","volume":"24","author":"K\u00fchn","year":"2020","journal-title":"Crit Care"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/antibiotics9030131","article-title":"Therapeutic drug monitoring of meropenem and piperacillin in critical illness\u2014experience and recommendations from one year in routine clinical practice","volume":"9","author":"Scharf","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/cc3993","article-title":"Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation","volume":"10","author":"Mariat","year":"2006","journal-title":"Crit Care"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/phar.2332","article-title":"Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study","volume":"39","author":"Philpott","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1248\/yakushi.130.87","article-title":"Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF)","volume":"130","author":"Hidaka","year":"2010","journal-title":"Yakuga Zasshi"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1128\/AAC.49.6.2421-2428.2005","article-title":"Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients","volume":"49","author":"Fish","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.ajkd.2013.08.015","article-title":"Pharmacokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treated with continuous venovenous hemodialysis","volume":"63","author":"Afshartous","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"e0153927","DOI":"10.1371\/journal.pone.0153927","article-title":"Clinical validation of therapeutic drug monitoring of imipenem in spent effluent in critically ill patients receiving continuous renal replacement therapy: a pilot study","volume":"11","author":"Wen","year":"2016","journal-title":"Plos One"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/45.5.701","article-title":"Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure","volume":"45","author":"Valtonen","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00003246-200003000-00005","article-title":"Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration","volume":"28","author":"Giles","year":"2000","journal-title":"Crit Care Med"},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1097\/00003246-200010000-00006","article-title":"Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration","volume":"28","author":"Ververs","year":"2000","journal-title":"Crit Care Med"},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000074527","article-title":"Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration","volume":"49","author":"Krueger","year":"2003","journal-title":"Chemotherapy"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1177\/0091270003260286","article-title":"Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients","volume":"43","author":"Robatel","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/0091270005280583","article-title":"Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients","volume":"45","author":"Isla","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00134-008-1034-7","article-title":"Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy","volume":"34","author":"Langgartner","year":"2008","journal-title":"Intensive Care Med"},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/jac\/dku413","article-title":"Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?","volume":"70","author":"Varghese","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijantimicag.2014.09.009","article-title":"Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration","volume":"45","author":"Jamal","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s43440-019-00056-3","article-title":"Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial","volume":"72","author":"Nowak-K\u00f3zka","year":"2020","journal-title":"Pharmacol Rep"},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ijantimicag.2011.01.026","article-title":"Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy","volume":"37","author":"Taccone","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2050-6511-13-14","article-title":"An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration","volume":"13","author":"D'Arcy","year":"2012","journal-title":"BMC Pharmacol Toxicol"},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/1120009X12Z.0000000006","article-title":"Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients","volume":"24","author":"Petejova","year":"2013","journal-title":"J Chemother"},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MAT.0000000000000689","article-title":"Pharmacokinetics of amikacin in critical care patients on extracorporeal device","volume":"64","author":"Ruiz-Ramos","year":"2018","journal-title":"ASAIO J"},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0091270004273949","article-title":"A pilot study of netilmicin pharmacokinetics during continuous venovenous hemodiafiltration","volume":"45","author":"Syka","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijantimicag.2012.10.018","article-title":"Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy","volume":"41","author":"Covajes","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijantimicag.2013.01.018","article-title":"Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?","volume":"41","author":"Udy","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.2004.02143.x","article-title":"Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"58","author":"DelDot","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1093\/jac\/dkt261","article-title":"A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy","volume":"68","author":"Beumier","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijantimicag.2011.04.010","article-title":"Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients","volume":"38","author":"Chaijamorn","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jsps.2014.08.005","article-title":"Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?","volume":"23","author":"Omrani","year":"2015","journal-title":"Saudi Pharm J"},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"e01179-20","DOI":"10.1128\/AAC.01179-20","article-title":"Effectiveness of vancomycin dosing guided by therapeutic drug monitoring in adult patients receiving extracorporeal membrane oxygenation","volume":"64","author":"Marella","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1097\/BCR.0b013e31825042fa","article-title":"Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy","volume":"33","author":"Akers","year":"2012","journal-title":"J Burn Care Res"},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11095-020-02820-0","article-title":"Development of vancomycin dose individualization strategy by Bayesian prediction in patients receiving continuous renal replacement therapy","volume":"37","author":"Oda","year":"2020","journal-title":"Pharmaceut Res"},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/aas.12897","article-title":"Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study","volume":"61","author":"Bakke","year":"2017","journal-title":"Acta Anaesthesiol Scand"},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FTD.0000000000000495","article-title":"Effect of extracorporeal membrane oxygenation on the new vancomycin dosing regimen in critically ill patients receiving continuous venovenous hemofiltration","volume":"40","author":"Yang","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5507\/bp.2012.092","article-title":"Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients","volume":"158","author":"Petejova","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5414\/CN106993","article-title":"Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD)","volume":"77","author":"Wilson","year":"2012","journal-title":"Clin Nephrol"},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/hdi.12704","article-title":"High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration","volume":"23","author":"Lim","year":"2019","journal-title":"Hemodial Int"},{"key":"R115-20250603","first-page":"243","article-title":"Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration","volume":"48","author":"Bellmann","year":"2010","journal-title":"Int J Clin Pharm Ther"},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","article-title":"Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study","volume":"18","author":"Zoller","year":"2014","journal-title":"Crit Care"},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ijantimicag.2017.04.002","article-title":"Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration","volume":"49","author":"Corcione","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcrc.2018.11.016","article-title":"Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK\/PD target attainment","volume":"50","author":"Barrasa","year":"2019","journal-title":"J Crit Care"},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkr551","article-title":"Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodia","volume":"67","author":"Wenisch","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s15010-012-0300-3","article-title":"Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy","volume":"41","author":"Preiswerk","year":"2013","journal-title":"Infection"},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ajkd.2015.03.001","article-title":"Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis","volume":"66","author":"Shotwell","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1472-6904-11-11","article-title":"An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration","volume":"11","author":"Spooner","year":"2011","journal-title":"BMC Clin Pharmacol"},{"key":"R123-20250603","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s001340100857","article-title":"Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration","volume":"27","author":"Wallis","year":"2001","journal-title":"Intensive Care Med"},{"key":"R124-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5114\/ait.2020.99605","article-title":"Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients\u2014new assessment","volume":"52","author":"Onichimowski","year":"2020","journal-title":"Anaesthesiol Intensiv Ther"},{"key":"R125-20250603","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/47.2.229","article-title":"Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients","volume":"47","author":"Traunm\u00fcller","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkh421","article-title":"Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration","volume":"54","author":"Fuhrmann","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R127-20250603","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13054-018-2278-4","article-title":"Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study","volume":"22","author":"Broeker","year":"2018","journal-title":"Crit Care"},{"key":"R128-20250603","doi-asserted-by":"crossref","first-page":"531","DOI":"10.5414\/CP203669","article-title":"PK\/PD study of tigecycline in severely infected patients with continuous renal replacement therapy","volume":"58","author":"Hong-huan","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000070997","article-title":"How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin","volume":"26","author":"Meyer","year":"2003","journal-title":"Kidney Blood Press Res"},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/49.1.129","article-title":"Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients","volume":"49","author":"Traunm\u00fcller","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.45.11.3148-3155.2001","article-title":"Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients","volume":"45","author":"Malone","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R132-20250603","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1128\/AAC.05987-11","article-title":"Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis","volume":"56","author":"Wilson","year":"2012","journal-title":"Antimicrob Agents Chermother"},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00228-016-2045-x","article-title":"Pharmacokinetics of cefoperazone\/sulbactam in critically ill patients receiving continuous venovenous hemofiltration","volume":"72","author":"Gao","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1067\/mcp.2000.105352","article-title":"Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval","volume":"67","author":"Banyai","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01582-09","article-title":"Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration","volume":"54","author":"Bilgrami","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R136-20250603","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1128\/AAC.00374-11","article-title":"Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration","volume":"55","author":"Akers","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R137-20250603","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1128\/AAC.00858-07","article-title":"Adsorption of amikacin, a significant mechanism of elimination by hemofiltration","volume":"52","author":"Tian","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40121-013-0012-8","article-title":"Amikacin pharmacokinetics during continuous veno-venous hemodialysis","volume":"2","author":"Lam","year":"2013","journal-title":"Infect Dis Ther"},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.therap.2020.10.005","article-title":"Alteration of the pharmacokinetics of aminoglycosides by adsorption in a filter during continuous renal replacement therapy. An in vitro assessment","volume":"76","author":"Baud","year":"2020","journal-title":"Therapie"},{"key":"R140-20250603","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","article-title":"Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy","volume":"46","author":"Pea","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s001340050424","article-title":"Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH)","volume":"23","author":"van der Werf","year":"1997","journal-title":"Intensive Care Med"},{"key":"R142-20250603","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mcp.2002.122526","article-title":"Tissue distribution of imipenem in critically ill patients","volume":"71","author":"Tegeder","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R143-20250603","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.01083-12","article-title":"Case-control study of drug monitoring of \u03b2-lactams in obese critically ill patients","volume":"57","author":"Hites","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R144-20250603","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R145-20250603","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R146-20250603","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/cc1516","article-title":"Clinical review: use of vancomycin in haemodialysis patients","volume":"6","author":"Launay-Vacher","year":"2002","journal-title":"Crit Care"},{"key":"R147-20250603","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-200140030-00003","article-title":"Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials","volume":"40","author":"Aminimanizani","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R148-20250603","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2215\/CJN.01840506","article-title":"Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis","volume":"1","author":"Czock","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R149-20250603","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0091270004265646","article-title":"Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers","volume":"44","author":"Dvorchik","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R150-20250603","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000353400","article-title":"Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy","volume":"59","author":"Corti","year":"2013","journal-title":"Chemotherapy"},{"issue":"suppl 5","key":"R151-20250603","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R152-20250603","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2011.07.004","article-title":"Dosing of colistin\u2014back to basic PK\/PD","volume":"11","author":"Bergen","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"R153-20250603","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1128\/AAC.01868-15","article-title":"Population pharmacokinetics of colistin methanesulfonate and colistin in critically ill patients with acute renal failure requiring intermittent hemodialysis","volume":"60","author":"Jacobs","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R154-20250603","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R155-20250603","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R156-20250603","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R157-20250603","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R158-20250603","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/jac\/dks257","article-title":"Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study","volume":"67","author":"Markou","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R159-20250603","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/IJNRD.S42791","article-title":"Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration","volume":"6","author":"Honore","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R160-20250603","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FTD.0b013e3182a8997c","article-title":"Determination by LC\u2013MS\/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration","volume":"36","author":"Leporati","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R161-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40620-014-0143-3","article-title":"Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies","volume":"28","author":"Mariano","year":"2015","journal-title":"J Nephrol"},{"key":"R162-20250603","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dkv031","article-title":"Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing","volume":"70","author":"Jitmuang","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R163-20250603","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijantimicag.2016.06.008","article-title":"Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"48","author":"Karaiskos","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R164-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R165-20250603","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R166-20250603","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R167-20250603","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1128\/AAC.01131-16","article-title":"Bayesian estimation of tobramycin exposure in patients with cystic fibrosis","volume":"60","author":"Barras","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R168-20250603","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1128\/AAC.00951-13","article-title":"Protein binding of \u03b2-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R169-20250603","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R170-20250603","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2009.135","article-title":"Drug dosing in patients with impaired renal function","volume":"86","author":"Brater","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R171-20250603","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R172-20250603","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1186\/cc12844","article-title":"Therapeutic drug monitoring of amikacin in septic patients","volume":"17","author":"Duszynska","year":"2013","journal-title":"Crit Care"},{"key":"R173-20250603","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000478969","article-title":"Implication of haemodiafiltration flow rate on amikacin pharmacokinetic parameters in critically ill patients","volume":"45","author":"Ruiz-Ramos","year":"2018","journal-title":"Blood Purif"},{"key":"R174-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"R175-20250603","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jac\/dkg403","article-title":"Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis","volume":"52","author":"Zelenitsky","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R176-20250603","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1525-139X.2008.00554.x","article-title":"Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?","volume":"22","author":"O'Shea","year":"2009","journal-title":"Semin Dial"},{"key":"R177-20250603","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270006286902","article-title":"Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis","volume":"46","author":"Dang","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R178-20250603","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2215\/CJN.02920707","article-title":"Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing","volume":"3","author":"Sowinski","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R179-20250603","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0091270006292987","article-title":"Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis","volume":"46","author":"Teigen","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R180-20250603","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.01762-12","article-title":"Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered","volume":"57","author":"Veinstein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R181-20250603","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/17425255.2021.1902985","article-title":"The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients","volume":"17","author":"Fiore","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R182-20250603","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9343(02)01476-6","article-title":"Pharmacokinetic dosing of aminoglycosides: a controlled trial","volume":"114","author":"Bartal","year":"2003","journal-title":"Am J Med"},{"key":"R183-20250603","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2125.1995.tb05719.x","article-title":"A suggested approach to once-daily aminoglycoside dosing","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"R184-20250603","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/FTD.0b013e3181f675c2","article-title":"Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients","volume":"32","author":"Delattre","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R185-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R186-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R187-20250603","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R188-20250603","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R189-20250603","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","article-title":"Cefepime free minimum concentration to minimum inhibitory concentration (fCmin\/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia","volume":"45","author":"Aitken","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R190-20250603","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"R191-20250603","first-page":"497","article-title":"Elevated \u03b2-lactam concentrations associated with neurological deterioration in ICU septic patients","volume":"81","author":"Beumier","year":"2014","journal-title":"Minerva Anestesiol"},{"key":"R192-20250603","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration\u2013toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R193-20250603","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R194-20250603","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/AAC.01595-08","article-title":"High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function","volume":"54","author":"Lamoth","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R195-20250603","doi-asserted-by":"crossref","first-page":"e00654-17","DOI":"10.1128\/AAC.00654-17","article-title":"Neurotoxic concentration of piperacillin during continuous infusion in critically Ill patients","volume":"61","author":"Quinton","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R196-20250603","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of \u03b2-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R197-20250603","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"R198-20250603","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.06389-11","article-title":"Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock","volume":"56","author":"Taccone","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R199-20250603","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/CCM.0000000000004326","article-title":"Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis","volume":"48","author":"Flannery","year":"2020","journal-title":"Crit Care Med"},{"key":"R200-20250603","doi-asserted-by":"crossref","first-page":"319S","DOI":"10.1592\/phco.21.18.319S.33904","article-title":"Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside","volume":"21","author":"Rodvold","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R201-20250603","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R202-20250603","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.00277-10","article-title":"Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired Pneumonia","volume":"56","author":"Rubino","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R203-20250603","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.01084-06","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections","volume":"51","author":"Meagher","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R204-20250603","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.00813-07","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections","volume":"52","author":"Passarell","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R205-20250603","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1128\/AAC.01114-09","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models","volume":"54","author":"Dudhani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R206-20250603","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/jac\/dkq226","article-title":"fAUC\/MIC is the most predictive pharmacokinetic\/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models","volume":"65","author":"Dudhani","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R207-20250603","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R208-20250603","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorl\u00ed","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R209-20250603","doi-asserted-by":"crossref","first-page":"e01367-17","DOI":"10.1128\/AAC.01367-17","article-title":"Pharmacokinetic\/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients","volume":"61","author":"Forrest","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R210-20250603","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1128\/AAC.03776-14","article-title":"Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin","volume":"58","author":"Phe","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R211-20250603","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/cir611","article-title":"Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system","volume":"53","author":"Pogue","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R212-20250603","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jinf.2010.11.013","article-title":"Risk factors for colistin-associated nephrotoxicity","volume":"62","author":"Rattanaumpawan","year":"2011","journal-title":"J Infect"},{"key":"R213-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R214-20250603","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jac\/dkp302","article-title":"A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?","volume":"64","author":"Li","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R215-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1399-6576.2011.02571.x","article-title":"Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy","volume":"56","author":"Vaara","year":"2012","journal-title":"Acta Anaesthesiol Scand"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:28:09Z","timestamp":1748957289000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":212,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000941","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}